Trial Profile

An Open Label, Multicenter, Non Randomized Phase II Study to Evaluate Antitumor Efficacy and Safety of GM-CSF (Sargramostim, Leukine) Associated With RCHOP Chemotherapy and Rituximab (MabThera) Maintenance in Patients With First-line Advanced Follicular Non Hodgkin's Lymphoma

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sargramostim (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab; Vincristine
Indications Non-Hodgkin's lymphoma
Focus Biomarker; Therapeutic Use

24 Mar 2012 Actual initiation date (19 Sep 2008) added as reported by European Clinical Trials Database.
24 Mar 2012 Status changed from not yet recruiting to recruiting as reported by European Clinical Trials Database.
13 May 2009 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com